Study of zanidatamab for advanced HER2-positive stomach cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study observes people with advanced HER2-positive stomach or esophageal cancer who are starting a treatment that includes zanidatamab. It collects information about their experiences and quality of life during treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have advanced stomach or esophageal cancer that is HER2-positive (confirmed by a test).
- Your doctor must plan to start you on a treatment that includes zanidatamab as your first therapy.
- You must be able to read, understand, and answer questions about your health and well-being.
- You must be 18 years or older when you start the zanidatamab treatment.
- You cannot have already received zanidatamab, nor can you be part of another clinical trial or expanded access program for this drug.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called zanidatamab in people with advanced solid tumors that have high levels of HER2 protein (called HER2-positive). It aims to see if zanidatamab can shrink or slow the growth of these tumors.
This trial tests a new targeted drug called zanidatamab given with standard chemotherapy before surgery for HER2-positive stomach or gastroesophageal junction cancer. It aims to shrink the tumor enough to allow successful removal, either for cancers that were initially too advanced for surgery or for those with high-risk features.
This trial tests adding zanidatamab (an antibody targeting HER2) to standard chemotherapy before and after surgery for operable HER2-positive stomach or esophagus cancer. It aims to see if this combination improves outcomes.
This study looks at how well the drug trastuzumab deruxtecan (T-DXd) works and how safe it is in people with advanced HER2-positive stomach or gastroesophageal junction cancer in China. It may be an option if you have already had other treatments.
This trial tests a new drug called zanidatamab combined with chemotherapy to shrink HER2-positive breast cancer before surgery. It may help improve treatment outcomes for people with stage 2 or 3 breast cancer that has not spread.
This phase 3 trial tests whether adding zanidatamab (a targeted antibody) to standard chemotherapy can improve outcomes for advanced HER2-positive biliary tract cancer. If you have this type of cancer that has spread or can't be removed, and you've had little or no prior treatment, this study might be an option.
Hear when a new Esophageal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.